The preclinical research of kinase inhibitors in traumatic brain injury (TBI)
Drug | Author/date | Injury model | Treatment | Pathological outcome | Clinical outcome |
---|---|---|---|---|---|
Sirolimus | Song et al. [38], 2015 | WDI mice | 2 mg/kg, i.p. 30 min after TBI | Neurons↑, IL-1β and TNF-α↓, microglial activation↓ | The NSS score↓, the score in the grip test↑ |
Chen et al. [39], 2019 | WDI mice | 3 mg/kg, i.p. 3 h after TBI | NLRP3 inflammasome↓, mitochondrial dysfunction↓, cortical neuron↑, IL-1β↑, IL-18↓ | mNSS scores↓, brain edema↓ | |
Jiang et al. [37], 2018 | CCI rats | 2 mg/kg, i.p. 1 h before TBI | TNF-α↑, IL-1β↑, IL-6↑ | mNSS score↑, brain edema↑ | |
Nikolaeva et al. [71], 2016 | CCI mice | 1 mg/kg, i.p. 1h after TBI | Damaged neurons↓, astrogliosis↓, C-side GFAP positive cells↓ | Latency time of MWM↑ | |
Ding et al. [70], 2015 | WDI mice | 2 mg/kg, i.p. 30 min after TBI | Neurons↑, apoptosis index↓ | NSS score↓ | |
Wang et al. [68], 2017 | WDI rats for daily 5 days | 3 mg/kg, i.p. 4 h after each WDI | Apoptosis↓, autophagy↑, mitophagy↑ | Footslips in the beam walking↓ | |
Fan et al. [69], 2018 | cTBI mice | Daily 0.5 mg/kg, i.p. at 1 h after cTBI | The infarct volume↓, glial scar↓, axon regeneration↑ | Footslips in the beam walking test↓ | |
Daily 1.5 mg/kg, i.p. at 1 h after cTBI | GFAP+ cell↓ | Latency in rotarod↑ | |||
Zhu et al. [35], 2014 | CHI mice | 4 μL 1.25 mmol/L or 12.5 mmol/L, ICV before CHI | - | 12.5 mmol/L worsened the performance in the hidden platform and probe trials↓ | |
Berdichevsky et al. [66], 2013 | Accelerated in vitro model of post-traumatic epilepsy | At 3 days in vitro | Lactate↓, LDH↓, axon sprouting in CA3 and DG↓, surviving CA3 and CA1 neurons↑, ictal event↓ | - | |
Guo et al. [64], 2013 | CCI mice | 6 mg/ kg, i.p. 1 h after TBI and continued once daily for 4 weeks | Neuronal death in the hippocampus↓, seizure frequency↓ | - | |
Butler et al. [67], 2016 | CCI mice | 3 mg/kg, 20–30 min after injury and continued once daily | sIPSC frequency↓, synaptic inhibition current↑, THIP-induced tonic current↑ | - | |
Dasatinib | Sun et al. [43], 2024 | WDI mice | 5 mg/kg, i.p. right after WDI | IL-6↓, RIPK3↓, necrosis↓ | - |
Wang et al. [59], 2023 | CCI mice | D 5 mg/kg + Q 50 mg/kg 1 month after CCI for 13 weeks | IL-1β↓, IL-6↓, p16+ and p21+ astrocytes↓, p16+ and p21+ microglia↓, NeuN+ cell↑ | Defect in the Barnes maze test↓, depressive-like behavior in the Forced Swim↓ | |
Yu et al. [42], 2016 | FPI mice | 25 mg/kg, i.p. 2 h after FPI | Positive cells in the typical lesion↓ | Latency in the rotarod↑ | |
Van Houcke et al. [72], 2023 | Stab-wound injury killifish | D 5 mg/kg + Q 50 mg/kg, i.p. | Progenitors↑, NGPs↑, mature neurons↑ | - | |
Imatinib | Su et al. [46], 2015 | CCI mice | 200 mg/kg, p.o. 45 min after TBI twice daily for 5 days | BBB leakage↓, lesion size↓, edema↓, tissue loss↓ | Deficit in MWM↓, the performance in probe trial↑ |
Sakai et al. [60], 2021 | CCI mice | 200 mg/kg, p.o. 12 h and 2 h before CCI and twice daily for 4 days after CCI | Iba1 immunoreactivity↓, pilocarpine-induced seizure severity↓, pilocarpine-induced seizure interval↓ | - | |
Pexidartinib | Wang et al. [61], 2020 | FPI mice | 290 mg/kg, p.o. for 21 days before FPI and continued after FPI | Microglia↓, infiltrated immune cells↓, apical dendritic spines↑, synaptic proteins↑, cell apoptosis↓, ER stress↓, neurite sprouting↑ | - |
Wang et al. [47], 2022 | CCI mice | 290 mg/kg, p.o. 90 min after CCI for 5 days or 30 days | 5 days: CD68+ M/M↓, GFAP+ astrocytes↓, Iba1+ M/M↓, apoptosis marker Bax↓, Ki67 cells↓ | Weight↓, NSS↓ | |
30 days: brain tissue loss↓, NeuN+ neurons↑ in male mice, gene of immune processes and phagocytosis in male↑ | NSS↑ in male, motor deficits in rotarod test↑ in female | ||||
Ruxolitinib | Chen et al. [73], 2021 | CCI mice | 0.44 mg/kg, i.p. 30 min after TBI | COX2↓, TfR1↓, GPX4↓, the shrinkage and hyperchromatic morphology of the Nissl bodies↑, degenerating cells↓, brain edema↓, iron-positive cells↓ | Motor dysfunction in the wire-grip test↓, latency in MWM↓, total distance in open field test↓ |
Peng et al. [49], 2023 | CCI mice | 0.44 mg/kg, i.p. 15 min or 6 h after TBI | Lesion volume↓, caspase-1↓, caspase-3↓, caspase-8↓, IL-1β↓, neurodegeneration↓, maintain the homeostasis of cathepsin B (↑ in the early, ↓ in the following) | Vestibulomotor dysfunction↓, latency in MWM↓, total distance in open field test↓ | |
Sunitinib | Welsbie et al. [50], 2019 | IA mice | 60 mg/kg, i.p. 24 h and 4h before IA, immediately once and daily for 3 weeks after IA | Retinal ganglion cells↑ | - |
Trametinib | Huang et al. [51], 2020 | CCI mice | 1 mg/kg for 7 days after CCI | Oligo2-positive cells↑, myelin basic protein↑, myelin oligodendrocyte glycoprotein↑, IL-1β↓, CD86↓, TNF-α↓, NOS2↓, IL-12↓, GM-CSF↓, microglia↓ | Revisiting error time in eight-arm radial maze assay↓, latency in MWM↓, latency in rotarod assay↑ |
Abrocitinib | Li et al. [13], 2022 | FPI mice | 10 mg/kg | The lesion size↓, hematoma↓, BBB integrity↑, cortical cerebral blood flow↑, neurons↑, apoptosis↓, neutrophils↓, microglia↓, M1 polarization↓, M2 polarization↑, IL-6↓, TNF-α↓, NF-κB↓, NLRP3↓, ASC↓, caspase-1↓, GSDMD↓, IL-1β↓, IL-18↓, pyroptosis↓ | mNSS score↓ |
↑: increase or promote; ↓: decrease or reduce; -: no relevant experiment. WDI: weight drop injury; IL: interleukin; TNF: tumor necrosis factor; NSS: neurological severity score; NLRP3: nucleotide-binding domain leucine-rich repeat and pyrin domain-containing protein 3; mNSS: modified NSS; CCI: controlled cortical impact; GFAP: glial fibrillary acidic protein; MWM: Morris water maze; cTBI: cryogenic TBI; ICV: intracerebroventricular; CHI: closed head injury; LDH: lactate dehydrogenase; CA: cornu ammonis; sIPSC: spontaneous inhibitory post-synaptic current; RIPK3: receptor-interacting protein kinase 3; D: dasatinib; Q: quercetin; FPI: fluid percussion injury; NGPs: non-glial progenitors; BBB: blood-brain barrier; Iba1: ionized calcium binding adapter molecule 1; ER: endoplasmic reticulum; M/M: microglia/macrophage; Bax: B-cell lymphoma 2-associated X protein; COX2: cyclooxygenase 2; GPX4: glutathione peroxidase 4; IA: impact acceleration; NF-κB: nuclear factor kappa B; i.p.: intraperitoneal; p.o.: oral; DG: dentate gyrus; NeuN: neuronal nuclear antigen